AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25402495
Drug: Zirconium cyclosilicate
RxNorm normalized name: ZIRCONIUM CYCLOSILICATE ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zirconium cyclosilicate 15 g daily for 28 days
Trial: 18818174
Drug: 1% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% glucose acetated Ringer solution containing Mg2+
Trial: 18818174
Drug: Glucose free
RxNorm normalized name: Glucose free hemofiltration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose free solution containing Na+ 130 mEq/L without Mg2+
Trial: 8935809
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ziprasidone
Trial: 1913698
Drug: Sinemet CR
RxNorm normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sinemet CR (50-200) controlled-release tablets
Trial: 1913698
Drug: Standard Sinemet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Sinemet (25-100) immediate-release tablets
Trial: 6409316
Drug: Combined measles,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined measles, mumps, and rubella vaccine (two different batches)
Trial: 26817809
Drug: Inspiratory muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory muscle training at 30% of maximal inspiratory pressure for 15 minutes twice a day, 7 days a week, for 12 weeks alongside standard medical treatment.
Trial: 26817809
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment only (control group).
Trial: 24837137
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m²) with zoledronic acid (group DZ)
Trial: 24837137
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m²) without zoledronic acid (group D)
Trial: 9543976
Drug: hyper-oxygenated fatty
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyper-oxygenated fatty acid esters solution
Trial: 2898536
Drug: Combined-modality therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality therapy (chemotherapy plus radiotherapy)
Trial: 2898536
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (SMF: streptozocin, mitomycin, and 5-fluorouracil)
Trial: 2898536
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (SMF)
Trial: 21639810
Drug: Ipilimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter)
Trial: 21639810
Drug: Dacarbazine (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (850 mg per square meter) plus placebo
Trial: 14748941
Drug: Antioxidant mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant mixture (Se 150 microg, retinyl acetate mg, ascorbic acid 120 mg, alpha‐tocopheryl succinate 20 mg)
Trial: 8198414
Drug: Ethamsylate (165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethamsylate (165 infants received the drug)
Trial: 2830918
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) 2.5 mg b.i.d.
Trial: 2830918
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) 5 mg b.i.d.
Trial: 2830918
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) 10 mg b.i.d.
Trial: 30187572
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of 2% lidocaine solution 20mL (LID, n=64)
Trial: 29364340
Drug: Antibiotic (Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic (Azithromycin 500mg)
Trial: 20626422
Drug: Conventionally placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventionally placed submerged implants (Group 1)
Trial: 20626422
Drug: Early-placed submerged
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early-placed submerged implants (Group 2)
Trial: 20626422
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 implants
Trial: 20626422
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 implants
Trial: 31107344
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIG), a 20% solution stabilized with L‐proline, FDA-approved for CIDP maintenance therapy.
Trial: 19403902
Drug: T12PR24 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T12PR24 group (telaprevir 1250 mg on day 1 and 750 mg every 8 hours for 12 weeks, plus peginterferon alfa‐2a and ribavirin for 24 weeks)
Trial: 8011392
Drug: 0.1 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mmol/kg gadodiamide injection
Trial: 8011392
Drug: 0.3 mmol/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mmol/kg gadodiamide injection
Trial: 8011392
Drug: Overall diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall diagnostic utility of gadodiamide injection
Trial: 8011392
Drug: Safety profile
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety profile of gadodiamide injection
Trial: 27778151
Drug: Low dietary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dietary intake of magnesium (<250 mg/day)
Trial: 27778151
Drug: High dietary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dietary intake of magnesium (>250 mg/day)
Trial: 25055838
Drug: DMCT (dose-matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMCT (dose-matched control treatment)
Trial: 24210600
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) therapy for 12 weeks
Trial: 22101701
Drug: SGIP acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGIP acupuncture therapy
Trial: 11602221
Drug: Propranolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (beta 1 and beta 2 receptor antagonist)
Trial: 11602221
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion before an injection of placebo
Trial: 29873956
Drug: MIN‐101 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIN‐101 32 mg
Trial: 29873956
Drug: MIN‐101 64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIN‐101 64 mg
Trial: 19930762
Drug: HFrD (hypercaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFrD (hypercaloric diet enriched with fructose, 3.5 g fructose/kg fat‐free mass per day, +35% energy intake)
Trial: 19930762
Drug: HGlcD (hypercaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HGlcD (hypercaloric diet enriched with glucose, 3.5 g glucose/kg fat‐free mass per day, +35% energy intake)
Trial: 17350525
Drug: Levobupivacaine 0.25%
RxNorm normalized name: levobupivacaine 0.25% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25% (19-mL bolus) followed by levobupivacaine 0.1% infusion
Trial: 17350525
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 microg (19-mL bolus) followed by levobupivacaine 0.05% with fentanyl 4 microg/mL infusion
Trial: 17350525
Drug: Clonidine 150
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 150 microg (19-mL bolus) followed by levobupivacaine 0.05% with clonidine 3 microg/mL infusion
Trial: 11929640
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives with 20 microg estrogen
Trial: 11929640
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives with 50 microg estrogen
Trial: 11229219
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate (660 mg) for 6 weeks (Group‐‐IIB)
Trial: 1091138
Drug: Complete dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete dietary supplement consisting of a beef serum hydrolysate, a glucose polymer, and medium‐chain triglycerides
Trial: 1091138
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients who did not receive the supplement)
Trial: 24667751
Drug: Glucose (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (200 kcal/250 ml)
Trial: 24667751
Drug: Sucrose (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (200 kcal/250 ml)
Trial: 24667751
Drug: High-fructose corn
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose corn syrup (HFCS) (200 kcal/250 ml)
Trial: 24667751
Drug: HFCS (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFCS (200 kcal/250 ml)
Trial: 9164415
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delavirdine mesylate (200 mg every 8 hours, 300 mg every 8 hours, 400 mg every 8 hours)
Trial: 9164415
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (300 mg every 8 hours)
Trial: 9164415
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delavirdine mesylate (all doses)
Trial: 2885638
Drug: Marrow depleted
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marrow depleted of T cells by treatment with monoclonal antibodies (anti CD4‐CD5‐CD8, group B)
Trial: 2885638
Drug: Marrow depleted
RxNorm normalized name: Sus scrofa bone marrow preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marrow depleted of T cells by treatment with monoclonal antibodies (anti CD2‐CD5‐CD7, group C)
Trial: 29412335
Drug: Art therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Art therapy (20 weekly sessions, 90 min/session)
Trial: 9817625
Drug: Citalopram (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20-60 mg/day)
Trial: 8507759
Drug: Monotherapy (single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (single-agent therapy)
Trial: 3324441
Drug: Nitrofurantoin or
RxNorm normalized name: nitrofurantoin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin or another appropriate antibiotic
Trial: 27764102
Drug: Seasonal Malaria
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) administered once per month from September to November.
Trial: 22956016
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block (BSCPB) with 20 mL of 0.525% ropivacaine
Trial: 22956016
Drug: Local wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local wound infiltration (LWI) with 20 mL of 0.525% ropivacaine
Trial: 22956016
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride solution (Control group)
Trial: 15728422
Drug: Moderately intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately intensive pool exercise therapy (twice a week for 12 weeks)
Trial: 11322867
Drug: Nesiritide (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesiritide (0.2 microgram/kg bolus followed by 0.01 microgram/kg/min continuous infusion)
Trial: 9675835
Drug: Disposable gastroscope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disposable gastroscope (G-F100)
Trial: 8002639
Drug: KW-2307 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 at 15 mg/m2
Trial: 8002639
Drug: KW-2307 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 at 20 mg/m2
Trial: 8002639
Drug: KW-2307 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 at 20 mg/m2 or higher doses
Trial: 8002639
Drug: KW-2307 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 at 25 mg/m2
Trial: 8002639
Drug: KW-2307 combined
RxNorm normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KW-2307 combined with cisplatin (CDDP) at 80 mg/m2
Trial: 818046
Drug: Intravenous Ara
RxNorm normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Ara A
Trial: 818046
Drug: Topical antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antiviral agents (IDU)
Trial: 28222801
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 6 × 10^6 hADSCs per 3 ml suspended in phosphate buffer saline
Trial: 28222801
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 3 ml phosphate buffer saline (placebo)
Trial: 17314444
Drug: Topical garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical garlic gel with betamethasone cream 0.1%
Trial: 17314444
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with betamethasone cream 0.1%
Trial: 15153582
Drug: Randomized controlled
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized controlled trials in podiatric medicine
Trial: 11161545
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (12 U/dose) for 5 h
Trial: 11161545
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (12 U/dose) for 5 days
Trial: 3056498
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate 1 mg (group A)
Trial: 3056498
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate 0.5 mg (group B)
Trial: 3056498
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 5 mg (group C)
Trial: 3056498
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 2.5 mg (group D)
Trial: 28668855
Drug: Acetium® lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetium® lozenge (slow-release L-Cysteine)
Trial: 26964163
Drug: Hooking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hooking therapy followed by safflower injection, once every 6 to 7 days, under local anesthesia. If efficacy was not satisfactory, a second treatment was given.
Trial: 26964163
Drug: Safflower injection
RxNorm normalized name: SAFFLOWER
DrugBank: Safflower (DB10905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower injection applied to three points of lumbar region, once a day for 2 sessions (7 treatments per session).
Trial: 16381068
Drug: Diazepam (0.19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.19 mg/kg oral)
Trial: 11479462
Drug: Reduced-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose recombinant tPA (8 mg bolus followed by 42 mg infusion)
Trial: 11479462
Drug: Urokinase (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase (1.5 million units as a 30-minute infusion)
Trial: 11479462
Drug: Reduced-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose recombinant tPA
Trial: 9725479
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate (25 mg)
Trial: 10805057
Drug: Ibuprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (200 mg)
Trial: 9725479
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate (25 mg) and Ibuprofen (200 mg) in association
Trial: 2686494
Drug: labetalol, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol, 2 mg/min to a maximum of 300 mg
Trial: 28159420
Drug: Postdischarge mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postdischarge mechanical compression device (MCD) therapy
Trial: 28159420
Drug: Inpatient mechanical
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient mechanical compression device (MCD) therapy
Trial: 21195076
Drug: PCV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV vaccine
Trial: 21195076
Drug: DPTaP-Hib vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPTaP-Hib vaccine
Trial: 19943711
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac solution (40 drops four times daily)
Trial: 19943711
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac solution (50 drops three times daily)
Trial: 15477437
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac solution
Trial: 17374331
Drug: PUVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA therapy
Trial: 26501236
Drug: Local corticosteroid
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroid therapy
Trial: 15166685
Drug: Lorazepam, 0.5-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam, 0.5-1.0 mg orally at bedtime for 7 days
Trial: 15166685
Drug: Zopiclone, 3.75-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone, 3.75-7.5 mg orally at bedtime for 7 days
Trial: 11248744
Drug: 5 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg/kg per day rhGH administered subcutaneously at 2200 h for four days
Trial: 9303394
Drug: Foscarnet cream
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Foscarnet cream
Trial: 8322650
Drug: 3-minute infusion
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-minute infusion of adenosine (140 micrograms/kg/min)
Trial: 8322650
Drug: 6-minute infusion
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-minute infusion of adenosine (140 micrograms/kg/min)
Trial: 8322650
Drug: Both 3-minute
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 3-minute and 6-minute infusions of adenosine
Trial: 3505706
Drug: Behaviorally oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviorally oriented group therapy (4 months)
Trial: 24886906
Drug: Early surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early surfactant treatment (Curosurf®)
Trial: 24886906
Drug: Late surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late surfactant treatment (Curosurf®)
Trial: 15752382
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg as a sugar-coated tablet (SCT) after fasting
Trial: 15752382
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg as a sugar-coated tablet (SCT) after food
Trial: 15752382
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg as a suspension after fasting
Trial: 11772328
Drug: Ileal‐release preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileal‐release preparation of budesonide
Trial: 10479170
Drug: PVL nadir
RxNorm normalized name: NAIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVL nadir >500 copies/mL